PT  - JOURNAL ARTICLE
AU  - DUMITRU CRISTINEL BADIU
AU  - ANCA ZGURA
AU  - CLAUDIA MEHEDINTU
AU  - BOGDAN HAINEALA
AU  - RODICA ANGHEL
AU  - XENIA BACINSCHI
TI  - The Role of Programmed Cell Death Receptor 1 in Lung Cancer
AID  - 10.21873/invivo.12794
DP  - 2022 Mar 01
TA  - In Vivo
PG  - 1007--1012
VI  - 36
IP  - 2
4099  - http://iv.iiarjournals.org/content/36/2/1007.short
4100  - http://iv.iiarjournals.org/content/36/2/1007.full
SO  - In Vivo2022 Mar 01; 36
AB  - Background/Aim: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. Patients and Methods: This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage. Results: Patients were diagnosed with non-microcellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PD-L1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%. Conclusion: No correlation was found between PD-L1 tumor expression and the age and sex of patients.